Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. This hybrid event will include a presentation detailing Anixa's recent corporate achievements, including the treatment of the first patient in its CAR-T based ovarian cancer clinical trial. The on-demand presentation will begin at 7:00 a.m. ET on September 12, 2022, with a replay accessible for 90 days. Anixa focuses on cancer and infectious disease therapies and collaborates with top research institutions.

SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24^th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).

The presentation will provide an overview of Anixa's business and highlight recent corporate achievements, including the treatment of the first patient in Anixa's CAR-T based ovarian cancer clinical trial.

Details of Anixa's presentation are as follows:

Event:	H.C. Wainwright 24th Annual Global Investment Conference
Date & Time:	On demand, beginning 7:00 a.m. ET, Monday, September 12, 2022
Webcast link:	https://journey.ct.events/view/6b15bb2c-5b4b-497a-9341-c2e2f7ee8542

A replay of the presentation will be available for 90 days at the link above or by visiting the Investors section of Anixa's website at https://ir.anixa.com/events.

Anixa management will also be available for one-on-one meetings throughout the conference.  Please contact your representative at H.C. Wainwright to request a meeting.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease.  Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the M^pro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.  To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani 
mcatelani@anixa.com 
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301615325.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is Anixa Biosciences presenting at the H.C. Wainwright conference?

Anixa Biosciences will present an update on its business and recent achievements, including the first patient treated in its CAR-T based ovarian cancer clinical trial.

When is Anixa Biosciences' presentation at the H.C. Wainwright conference?

The presentation will be available on demand starting at 7:00 a.m. ET on September 12, 2022.

Where can I watch Anixa Biosciences' presentation?

You can watch the presentation at the provided webcast link or visit Anixa's Investors section on their website.

What recent achievements will Anixa highlight in their presentation?

Anixa will highlight the treatment of its first patient in a clinical trial for CAR-T based ovarian cancer therapy.

How long will the presentation replay be available?

The replay of the presentation will be available for 90 days after the initial airing on September 12, 2022.